

# Genetic Deletion of p90 Ribosomal S6 Kinase 2 Alters Patterns of 5-Hydroxytryptamine<sub>2A</sub> Serotonin Receptor Functional Selectivity

Ryan T. Strachan, Noah Sciaky, Mark R. Cronan, Wesley K. Kroeze, and Bryan L. Roth

Department of Biochemistry, Case Western Reserve University Medical School, Cleveland, Ohio (R.T.S.); Departments of Pharmacology (N.S., W.K.K., B.L.R.), Biochemistry and Biophysics (M.R.C.), and Medicinal Chemistry (B.L.R.), University of North Carolina at Chapel Hill Medical School, Chapel Hill, North Carolina

Received October 2, 2009; accepted November 19, 2009

## ABSTRACT

The concept of functional selectivity has now thoroughly supplanted the previously entrenched notion of intrinsic efficacy by explaining how agonists and antagonists exhibit a range of efficacies for distinct receptor-mediated responses. It is noteworthy that functional selectivity accommodates significant changes in efficacy resulting from differential expression of G protein-coupled receptor modifying proteins (i.e., “conditional efficacy”)—a phenomenon with profound implications for drug discovery. We have uncovered a novel regulatory mechanism whereby p90 ribosomal S6 kinase 2 (RSK2) interacts with 5-hydroxytryptamine<sub>2A</sub> (5-HT<sub>2A</sub>) serotonin receptors and attenuates receptor signaling via direct receptor phosphorylation (*Proc Natl Acad Sci U S A* **103**:4717–4722, 2006; *J Biol Chem* **284**:5557–5573, 2009). This discovery, together with the mounting evidence for conditional efficacy,

suggested to us that 5-HT<sub>2A</sub> agonist signaling might be disproportionately affected by alterations in RSK2 expression. To test this hypothesis, we evaluated a chemically diverse set of 5-HT<sub>2A</sub> agonists at three readouts of 5-HT<sub>2A</sub> receptor activation in both wild-type (WT) and RSK2 knockout (KO) mouse embryonic fibroblasts (MEFs). Here we report that 5-HT<sub>2A</sub> receptor agonist efficacies were significantly and variably augmented in RSK2 KO MEFs compared with WT MEFs. As a result, relative agonist efficacies were significantly altered, and even reversed, between WT and RSK2 KO MEFs for a single effector readout. This study provides the first evidence that deletion of a single kinase can elicit profound changes in patterns of agonist functional selectivity.

Ligand “intrinsic efficacy” or “intrinsic activity” (i.e., relative to a reference agonist) defines the magnitude of response that a given ligand imparts to a biological system (Stephenson, 1956). The classic view of intrinsic efficacy assumes that a ligand’s ability to impart (or reduce) a stimulus once bound

to the receptor is an inherent property of the ligand-receptor complex and is system-independent (i.e., rank orders of efficacy are static across all receptor responses) (Kenakin, 2002). However, a plethora of recent studies at receptor tyrosine kinases and G protein-coupled receptors (GPCRs) have unequivocally demonstrated that ligands exhibit a wide range of efficacies for different receptor behaviors (i.e., rank orders of efficacy are dynamic across various receptor responses) (Roth and Chuang, 1987; Mailman, 2007; Urban et al., 2007; Wilson et al., 2009). To address these observations and to provide a unifying conceptual framework, the related concepts of “functional selectivity” (Ghosh et al., 1996), “agonist-

This work was supported by the National Institutes of Health National Institute of Mental Health Psychoactive Drug Screening Program [Grants R01-MH61887, U19-MH82441]; the Michael Hooker Chair for Therapeutics and Translational Proteomics; and the Michael Hooker Program in Translational Proteomics and Therapeutics.

Article, publication date, and citation information can be found at <http://molpharm.aspetjournals.org>.  
doi:10.1124/mol.109.061440.

**ABBREVIATIONS:** GPCR, G protein-coupled receptor; RSK2, p90 ribosomal S6 kinase 2; 5-HT, serotonin, 5-hydroxytryptamine; WT, wild type; KO, knockout; SB242084, 6-chloro-2,3-dihydro-5-methyl-*N*-[6-[(2-methyl-3-pyridinyl)oxy]-3-pyridinyl]-1*H*-indole-1-carboxamide dihydrochloride hydrate; IP, inositol phosphate; AA, arachidonic acid; ERK, extracellular signal-regulated kinase; DOI, (±)-2,5-dimethoxy-4-iodoamphetamine hydrochloride; quipazine, 2-(1-piperazinyl)-quinoline maleate; 5-methoxy-DMT, 5-methoxy-*N,N*-dimethyltryptamine; *m*-CPP, 1-(*m*-chlorophenyl)-piperazine; SCH-23390, *R*(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine hydrochloride; α-Me-5-HT, α-methyl serotonin; MK212, 6-chloro-2-(1-piperazinyl)pyrazine hydrochloride; MDL-100907, *R*(+)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol; DMEM, Dulbecco’s modified Eagle’s medium; FBS, fetal bovine serum; FLIPR, Fluorometric Imaging Plate Reader; RFU, relative fluorescence unit; PBS, phosphate-buffered saline; ANOVA, analysis of variance; MEF, mouse embryonic fibroblast; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]propanesulfonate.

directed trafficking of receptor stimulus" (Kenakin, 1995; Berg et al., 1998b), "biased agonism" (Kenakin, 2007), and "pluridimensionality of signaling" (Galandrin and Bouvier, 2006) (collectively referred to here as "functional selectivity") have emerged.

The capacity for ligands to elicit a spectrum of receptor behaviors is well documented for the  $G_{\alpha_q}$ -coupled 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> serotonin receptors. 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors are essential for mediating various functions of 5-HT in both central and peripheral tissues (e.g., modulation of mood and perception, regulation of appetite, and platelet aggregation) and are targeted by multiple drugs (Kroeze and Roth, 1998; Berger et al., 2009). In what are now considered classic studies, the lab of Clarke and Berg (Berg et al., 1998a; Moya et al., 2007) convincingly demonstrated that the relative rank orders of efficacy for chemically diverse agonists at 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors were reversed between phospholipase C  $\beta$ -mediated inositol phosphate (IP) accumulation and phospholipase A2-mediated arachidonic acid (AA) release. Likewise, Kurrasch-Orbaugh et al. (2003) reported that rank orders of efficacy were reversed for several classes of 5-HT<sub>2A</sub> agonists comparing IP accumulation and AA release. Significantly, the pleiotropic nature of 5-HT<sub>2</sub> ligands was highlighted in a recent study wherein the 5-HT<sub>2C</sub> selective "antagonist" SB242084 both antagonizes 5-HT<sub>2C</sub>-mediated AA release and promotes IP accumulation (De Deurwaerdere et al., 2004). In addition, in vitro and in vivo findings have demonstrated that 5-HT<sub>2A</sub>-selective ligands behave as "inverse agonists" at IP accumulation while simultaneously acting as agonists by promoting receptor internalization (Berry et al., 1996; Willins et al., 1999; Bhatnagar et al., 2001; Gray and Roth, 2001). Such pathway-specific reversals in relative efficacy are incompatible with classic notions of intrinsic efficacy and are considered benchmark examples of functional selectivity.

As seen for 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors, bona fide receptor-based functional selectivity manifests as a reversal in relative efficacies at different pathways. This behavior is not predicted by the classic concept of intrinsic efficacy and can only be explained by agonists stabilizing/promoting different receptor active states (Kenakin, 2007). It follows that the functional selectivity concept, unlike the concept of ligand intrinsic efficacy, ascribes quality to efficacy. Thus, ligand-specific receptor conformations can elicit multiple effector responses, including G protein activation; phosphorylation, desensitization, and internalization; formation of receptor dimers and oligomers; and interaction with auxiliary membrane and cytosolic proteins (Kenakin, 2002; Urban et al., 2007). In fact, GPCR-interacting proteins such as protein-coupling factors and receptor activity-modifying proteins (Christopoulos et al., 2003) have been shown to have profound effects on ligand efficacy (Kenakin, 2002). In addition, recent in vitro and in vivo evidence suggests that  $\beta$ -arrestins, in addition to their classic roles as GPCR-interacting proteins and negative regulators of GPCR signaling, are required for the signaling and functionally selective responses of several ligands (Lefkowitz and Shenoy, 2005; Abbas and Roth, 2008; Schmid et al., 2008). Accordingly, ligand efficacy is clearly conditional upon the expression of auxiliary modifying proteins within the cellular milieu (a phenomenon referred to as "conditional efficacy") (Kenakin, 2002). Therefore, it is conceivable that cell type-specific expression of

additional GPCR-interacting proteins such as kinases could result in differential modulation of ligand efficacy (Allen et al., 2008), although unequivocal evidence for such a phenomenon is not yet available.

We have recently uncovered a novel regulatory mechanism whereby the downstream extracellular signal regulated kinase (ERK)/mitogen-activated protein kinase effector, RSK2, interacts with 5-HT<sub>2A</sub> serotonin receptors and attenuates receptor signaling via direct receptor phosphorylation (Sheffler et al., 2006; Strachan et al., 2009). Together with the mounting evidence for conditional efficacy and with reports of phosphorylation-mediated stabilization of individual receptor conformations, we hypothesized that 5-HT<sub>2A</sub> agonist signaling would thus be disproportionately affected by changes in RSK2 expression. More explicitly, we wanted to determine whether genetic deletion of RSK2 differentially affected ligand efficacy. To this end, we performed a focused screen evaluating the effect of RSK2 expression (i.e., in WT and RSK2 KO MEFs) on the signaling of a chemically diverse panel of 5-HT<sub>2A</sub> receptor agonists at several readouts of 5-HT<sub>2A</sub> signaling (i.e., IP accumulation, Ca<sup>2+</sup> release, and ERK1/2 phosphorylation).

In this study, we provide evidence to both support and extend the emerging concepts of functional selectivity and conditional efficacy by showing that the relative efficacies of 5-HT<sub>2A</sub> agonists are reversed 1) between different pathways in WT MEFs and 2) between WT and RSK2 KO MEFs at a single pathway. It is noteworthy that genetic deletion of RSK2 results in significant and variable increases in the relative efficacy, but not potency, of a diverse panel of 5-HT<sub>2A</sub> agonists. These data demonstrate that the signaling of 5-HT<sub>2A</sub> receptor agonists is disproportionately regulated by RSK2. Significantly, this study provides the first evidence that deletion of a single kinase modulates patterns of agonist functional selectivity at a GPCR. Moreover, this finding has profound implications for drug discovery in particular and molecular pharmacology in general.

## Materials and Methods

**Materials.** Cell culture reagents were supplied by Invitrogen (Carlsbad, CA) and Cambrex (East Rutherford, NJ). 5-HT, ( $\pm$ )DOI, quipazine, 5-methoxy-DMT, *m*-CPP, SCH-23390,  $\alpha$ -Me-5-HT, LiCl, probenecid, porcine gelatin, paraformaldehyde, Triton X-100, and all other standard reagents were supplied by Sigma-Aldrich (St. Louis, MO). MK212 was obtained from Tocris Bioscience (Ellisville, MO). MDL-100907 and lisuride [1,1-diethyl-3-((6a*R*,9*S*)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-*fg*]quinolin-9-yl)urea] were acquired as detailed previously (Willins et al., 1999). [*myo*-<sup>3</sup>H]inositol (21.7 Ci/mmol) was obtained from PerkinElmer Life and Analytical Sciences (Waltham, MA). Multiwell imaging plates (96- and 384-well) were supplied by Greiner Bio-One (Monroe, NC). Hoechst, concanavalin-A conjugated to Alexa Fluor 488 nm, and goat anti-rabbit secondary antibody conjugated to Alexa Fluor 594 nm were supplied by Invitrogen. Normal goat serum was obtained from Millipore (Billerica, MA).

**Cell Culture.** This study used polyclonal populations of WT and RSK2 KO MEFs stably expressing similar amounts of recombinant 5-HT<sub>2A</sub> receptors (WT  $B_{\max}$  = 1058  $\pm$  53 fmol/mg protein; RSK2 KO  $B_{\max}$  = 731  $\pm$  57 fmol/mg protein) as determined via radioligand binding assays (Gray et al., 2001). These were generated previously by Sheffler et al. (2006) and were shown to express similar amounts of surface receptors. Although MEFs endogenously express low levels of 5-HT<sub>2A</sub> receptors, the overexpressing MEFs were chosen for

this study given their robust performance in scintillation proximity assays. Fibroblasts were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1 mM sodium pyruvate, 100 U/ml penicillin, 100 µg/ml streptomycin, and 4 µg/ml puromycin. Cells were grown at 37°C in a humidified environment in the presence of 5% CO<sub>2</sub>.

**Fluorometric Imaging Plate Reader Analysis of Intracellular Ca<sup>2+</sup> Release.** Intracellular Ca<sup>2+</sup> release was measured using a Fluorometric Imaging Plate Reader (FLIPR<sup>Tetra</sup>) and Ca<sup>2+</sup> assay kit (Molecular Devices, Sunnyvale, CA) as detailed previously (Strachan et al., 2009). In brief, 30,000 cells were plated into black-walled, clear-bottomed 96-well tissue culture plates in dialyzed culture medium (DMEM, 5% FBS dialyzed to <0.05 nM 5-HT, 1 mM sodium pyruvate, 100 U/ml penicillin, and 100 µg/ml streptomycin). The following day, cells were treated with Ca<sup>2+</sup> assay buffer (20 mM HEPES, 1× Hanks' balanced salt solution, 2.5 mM probenecid, and Ca<sup>2+</sup> assay reagent, pH 7.4) for 1 h at 37°C and equilibrated to room temperature before drug addition. The FLIPR<sup>Tetra</sup> was programmed to add agonist approximately 10 s after establishing baseline relative fluorescence unit (RFU) values (excitation, 470–495; emission, 515–575 nm). RFU values were collected every second for 5 min, and average baseline values were subtracted from maximum RFU values for each well. Baseline-subtracted values were normalized to cell number, analyzed by nonlinear regression (GraphPad Software Inc., San Diego, CA), and expressed relative to maximal 5-HT signaling at WT MEFs (set to 100%). The *F* test was used to determine statistical significance of the fit parameters EC<sub>50</sub> and *E*<sub>max</sub> (defined as *p* < 0.05). Agonist specificity was confirmed in control experiments wherein the selective 5-HT<sub>2A</sub> receptor antagonist MDL-100907 (1 µM) completely blocked the Ca<sup>2+</sup> response elicited by an EC<sub>80</sub> of agonist (data not shown).

**Analysis of Inositol Phosphates.** Inositol phosphate (IP) accumulation was measured using the scintillation proximity assay method exactly as detailed previously (Bourdon et al., 2006; Strachan et al., 2009). In brief, 30,000 cells were plated into 96-well tissue culture plates in dialyzed culture medium. The cells were inositol-starved for 1.5 h and incubated with 100 µl of labeling medium (inositol-free basal medium Eagle's, 5% dialyzed FBS, and 0.01 µCi/µl [<sup>3</sup>H]inositol) for 18 h at 37°C. The labeling medium was removed, and agonists were diluted in assay buffer (1× Hanks' balanced salt solution, 24 mM NaHCO<sub>3</sub>, 11 mM glucose, and 35 mM LiCl, pH 7.4) and added to the cells for 1 h at 37°C. The assay was terminated by the addition of 50 mM formic acid, and the supernatant was incubated with 0.2 mg yttrium silicate beads (Amersham, Chalfont St. Giles, Buckinghamshire, UK). Radioactivity in the form of [<sup>3</sup>H]inositol phosphate was measured via scintillation counting (Wallac Microbeta TriLux; PerkinElmer Life and Analytical Sciences). Baseline-subtracted values were normalized to cell number, analyzed by nonlinear regression (GraphPad Software), and expressed relative to maximal 5-HT signaling at WT MEFs (set to 100%). The *F* test was used to determine statistical significance of the fit parameters EC<sub>50</sub> and *E*<sub>max</sub> (defined as *p* < 0.05). Agonist specificity was confirmed in control experiments, wherein the selective 5-HT<sub>2A</sub> receptor antagonist MDL-100907 (1 µM) completely blocked IP accumulation elicited by an EC<sub>80</sub> of agonist (data not shown).

**High-Content Immunofluorescence Microscopy.** Here, we developed a novel high-content microscopic/automated image analysis approach to generate concentration-response curves for ERK1/2 phosphorylation in WT and RSK2 KO MEFs. In particular, we developed an extremely versatile triple-fluorescence labeling method that uses information gained from nuclear (Hoechst, 320 nm) and plasma membrane (concanavalin-A, 488 nm) staining to generate cellular masks (i.e., segmentation during image processing), which are then used to quantify the fluorescence intensity of the third fluorophore representing the protein of interest (referred to here as the "signal channel," 594 nm) in distinct cellular compartments. It is noteworthy that after the testing of several lectins, concanavalin-A produced the most reliable cellular masks. Thus, the use of con-

cavalin-A was crucial to the success and general applicability of this approach. In this study, we detected ERK1/2 phosphorylation using a primary antibody specific for ERK1/2 phosphorylation and an Alexa Fluor 594-conjugated secondary antibody. In brief, WT and RSK2 KO MEFs were plated onto 0.2% gelatin-coated black-walled, clear- and thin-bottomed 384-well tissue culture plates (Greiner Bio-One, Monroe, NC) in dialyzed culture medium at a density of 25,000 and 15,000 cells/well, respectively. Twenty-four hours later, the cells were washed with serum-free medium (DMEM, 100 U/ml penicillin, and 100 µg/ml streptomycin) and then serum-starved for 18 h. For the initial time course experiments (0–30 min), cells expressing 5-HT<sub>2A</sub> receptors were stimulated with 10 µM drug. For all subsequent experiments, we used the liquid handling capability of a FLIPR<sup>Tetra</sup> to simultaneously dispense concentrated drug solutions (final concentration range of 10 µM to 10 pM, performed in duplicate) into 384-well plates. Cells were treated with agonist for 5 min at 37°C, which we determined from time course experiments to produce maximal ERK1/2 phosphorylation for all agonists in both cell lines. After stimulation, the cells were immediately placed on ice, rinsed with ice-cold phosphate-buffered saline (PBS) wash buffer (PBS + 0.5 mM CaCl<sub>2</sub>, pH 7.4), and incubated with fixative (4% paraformaldehyde, PBS + 0.5 mM CaCl<sub>2</sub>, pH 7.4) to terminate activation. After 30 min at 25°C, the cells were washed and then permeabilized with 0.3% Triton X-100 for 30 min on ice. The permeabilized cells were incubated with blocking buffer (5% normal goat serum and PBS + 0.5 mM CaCl<sub>2</sub>, pH 7.4) for 1 h at 25°C and subsequently incubated with blocking buffer containing a phospho-ERK1/2-specific antibody (Thr202/Tyr204, 1:1000; Cell Signaling Technology, Inc., Danvers, MA) for 18 h at 4°C. The following day, the cells were extensively washed and incubated for 1 h at 25°C with blocking buffer containing Hoechst (5 µg/ml), concanavalin-A conjugated to Alexa Fluor 488 (20 µg/ml), and a goat anti-rabbit secondary antibody conjugated to Alexa Fluor 594 (1:200). The cells were extensively washed and incubated with fixative for 20 min at 4°C. Plates were then stored at 4°C in wash buffer before imaging.

Imaging was performed on a BD Pathway 855 High Content Bioimager (BD Biosciences, San Jose, CA) using the Olympus UAPO40X/340 objective lens (Olympus, Tokyo, Japan). We developed a workflow that used infrared laser autofocus, triple excitation/emission parameters (nuclear, 380/435 nm; plasma membrane, 488/515 nm; signal channel, 555/645 nm), and montaging of nine adjacent fields to produce superimposable nuclear, plasma membrane, and signal-channel images. The images were then exported to CellProfiler (Broad Institute Imaging Platform, Cambridge, MA) for image processing and analysis. In particular, we developed a macropipeline within CellProfiler that produced reliable cell segmentation wherein Hoechst and concanavalin-A intensities are used stepwise to generate nuclear, whole-cell, and cytoplasmic cell masks (Fig. 1A). Using this approach, we could measure the 594 nm intensity within defined cellular regions. Baseline-subtracted, whole-cell 594 nm mean intensity values corresponding to ERK1/2 phosphorylation were then analyzed via nonlinear regression (GraphPad Software) and expressed relative to the *E*<sub>max</sub> for 5-HT in WT MEFs. Statistical significance of ERK1/2 time course data were determined by one-tailed paired *t* test (defined as *p* < 0.05). The *F* test was used to determine statistical significance of the fit parameters EC<sub>50</sub> and *E*<sub>max</sub> (defined as *p* < 0.05). Assay quality was assessed using the *Z'* factor calculation of Zhang et al. (1999). Agonist specificity was confirmed in control experiments wherein the selective 5-HT<sub>2A</sub> receptor antagonist MDL-100907 (1 µM) completely blocked ERK1/2 phosphorylation elicited by an EC<sub>80</sub> concentration of agonist (shown for 5-HT in Fig. 1B).

**Immunoblotting.** Western blot measurements of ERK1/2 phosphorylation were performed according to Sheffler et al. (2006). In brief, WT and RSK2 KO MEFs were plated onto six-well plates in dialyzed culture medium at a density of 150,000 cells/well and serum-starved for approximately 18 h before the experiment. During the experiment, the cells were treated with 10 µM 5-HT for various times (0–30 min) at 37°C and then immediately placed on ice,




washed twice with cold PBS, and lysed (50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 1.0% CHAPS, EDTA-free protease inhibitor cocktail (Roche Applied Science, Branford, CT), 50 mM NaF, 50 mM  $\beta$ -glycerol phosphate, 0.1 mM  $\text{Na}_3\text{VO}_4$ , and 5 mM  $\text{Na}_4\text{P}_2\text{O}_7$ , pH 7.5). The supernatants were collected after centrifugation (16,000g at 4°C for 20 min) and stored at -20°C until further use. To measure ERK1/2 phosphorylation, equal amounts of protein were separated on 10% SDS-polyacrylamide gel electrophoresis gels and immunoblotted using standard procedures (Gray et al., 2001). Nitrocellulose blots were incubated with blocking buffer (Tris-buffered saline, 0.1% Tween 20, and 5% nonfat dehydrated milk) and then probed with the phospho-ERK1/2-specific antibody (Thr202/Tyr204, 1:1000; Cell Signaling Technology, Inc.) diluted in phospho-blocking buffer (Tris-buffered saline, 0.1% Tween 20, and 5% bovine serum albumin) or the ERK1/2 antibody (p44/42, 1:1000; Cell Signaling Technology, Inc.) diluted in standard blocking buffer. The primary antibodies were detected using the goat anti-rabbit secondary antibody conjugated to horseradish peroxidase (1:1000; Vector Laboratories, Burlingame, CA) and the SuperSignal West Pico chemiluminescent sub-

strate (Thermo Fisher Scientific, Rockford, IL). Immunoreactive bands were quantified using Kodak imaging software (Eastman Kodak, New Haven, CT).

**Statistical Analysis of Ligand Rank Order of Efficacy.** Relative agonist efficacies were analyzed using one-way ANOVA (significance set as  $p < 0.05$ ) and significant differences between groups (set as  $p < 0.05$ ) were subsequently identified via the Tukey-Kramer unplanned multiple comparisons test adjusted for unequal sample size (GraphPad Software). Mean relative agonist efficacies were then arranged in descending order and assigned to statistically homogeneous groups (labeled "a" through "f" in Table 4) such that significant differences in rank order were denoted by changes in group membership. Thus, agonists with nonoverlapping group assignments were considered to be significantly different.


## Results

**Validation of a Novel High-Content Microscopic Approach for ERK1/2 Phosphorylation.** In this study,



**Fig. 1.** Development of a novel triple-fluorescence high-content microscopic assay in 384-well plates to rapidly measure ERK1/2 phosphorylation in WT and RSK2 KO MEFs. A, diagram showing stepwise generation of nuclear (Hoechst 320), whole-cell (concanavalin-A 488), and cytoplasmic cell masks subsequently used to measure fluorescence intensity of the signal channel (594 nm) in distinct cellular regions. This approach incorporates the nearly limitless application of state-specific antibodies (e.g., phospho-specific) and fluorescently labeled proteins to quantify receptor responses. Moreover, segmenting the cell into distinct regions allows us to extract a variety of signaling phenotypes with customizable CellProfiler image analysis software. B, the triple-fluorescence technique was used to generate full concentration-response curves for ERK1/2 phosphorylation in WT and RSK2 KO MEFs after 5-min agonist treatment. The workflow shown here describes the steps used to measure ERK1/2 phosphorylation (594 nm, see representative images) within whole-cell masks after 5-HT treatment. Concentration-response curves for 5-HT-induced ERK1/2 phosphorylation in WT (■) and RSK2 KO (○) MEFs highlight the robustness ( $Z'$  factor = 0.54) and reproducibility of the triple-fluorescence technique. Values represent the mean  $\pm$  S.E.M. of 18 independent experiments performed in duplicate. Also shown are representative results (bottom right, mean  $\pm$  S.E.M.) in which the 5-HT<sub>2A</sub>-selective antagonist MDL-100907 (1  $\mu$ M) blocked the response to 5-HT (EC<sub>80</sub> concentration). Identical results were obtained for all agonists at both cell lines (data not shown).

**5-HT<sub>2A</sub> Agonist Responses for Diverse Agonists Are Differentially Altered by Genetic Deletion of RSK2.** We next determined how genetic deletion of RSK2 might affect the signaling of a structurally diverse panel of 5-HT<sub>2A</sub> receptor agonists. In agreement with our recent studies (Strachan



Agonist potencies ( $EC_{50}$ ) and relative efficacies ( $E_{\max}$ ) represent the average of four to five independent experiments.  $pEC_{50}$  values are represented as  $-\log$  of  $EC_{50}$ , given as molar values.

Agonist	Agonist Potency EC <sub>50</sub> (pEC <sub>50</sub> ± S.E.M.)			Relative Agonist Efficacy (E <sub>max</sub> ± S.E.M.)			E <sub>max</sub> <sup>RSK2KO</sup> /E <sub>max</sub> <sup>WT</sup>
	WT MEFs	RSK2 KO MEFs	F Test, <i>p</i> Value	WT MEFs	RSK2 KO MEFs	F Test, <i>p</i> Value	
	<i>nM</i>			<i>%</i>			
5-HT	134 (6.87 ± 0.03)	57.8 (7.24 ± 0.11)	0.0309	99.1 ± 1.2	209 ± 8.5	<0.0001	2.1
DOI	12.4 (7.91 ± 0.10)	8.51 (8.07 ± 0.10)	0.7145	71.7 ± 2.4	211 ± 13	<0.0001	2.9
Quipazine	188 (6.73 ± 0.09)	140 (6.85 ± 0.15)	0.7010	82.7 ± 2.9	220 ± 14	<0.0001	2.7
5-Methoxy-DMT	590 (6.23 ± 0.13)	386 (6.41 ± 0.15)	0.6487	66.6 ± 4.0	224 ± 14	<0.0001	3.4
Lisuride	3.52 (8.45 ± 0.57)	5.99 (8.22 ± 0.20)	0.7450	17.1 ± 2.6	63.1 ± 3.8	<0.0001	3.7
<i>m</i> -CPP	167 (6.78 ± 0.19)	231 (6.64 ± 0.09)	0.5364	27.8 ± 2.4	90.0 ± 3.6	<0.0001	3.2
SCH-23390	16.3 (7.79 ± 0.30)	24.6 (7.61 ± 0.08)	0.5342	14.0 ± 1.5	33.9 ± 1.1	<0.0001	2.4
α-Me-5-HT	178 (6.75 ± 0.04)	68.9 (7.16 ± 0.05)	<0.0001	95.4 ± 1.9	134 ± 3.0	<0.0001	1.4
MK212	3390 (5.47 ± 0.09)	2330 (5.63 ± 0.05)	0.1148	80.4 ± 5.7	152 ± 5.0	<0.0001	1.9

Because a major aim was to determine whether genetic deletion of RSK2 differentially modulates ligand efficacy, we generated relative efficacy ratios (i.e.,  $E_{\max}^{\text{RSK2KO}}/E_{\max}^{\text{WT}}$  values) for each response to quantify an agonist's propensity to signal in the absence of RSK2. It is interesting that we found that  $E_{\max}^{\text{RSK2KO}}/E_{\max}^{\text{WT}}$  values differed considerably for each agonist and response (Tables 1–3), with the largest changes observed for IP accumulation and ERK1/2 phosphorylation. The partial agonists 5-methoxy-DMT (3.4-fold), *m*-CPP (3.2-

Similar to our observations with partial agonists, highly efficacious ligands such as 5-HT (2.1-fold) and  $\alpha$ -Me-5-HT (1.4-fold) were differentially sensitive to genetic deletion of RSK2.  $\alpha$ -Me-5-HT behaved as a full agonist in WT MEFs, whereas it was substantially less responsive for IP accumulation in RSK2 KO MEFs (Fig. 4F). This behavior could not be explained by saturation of the response system because

A comparison of agonist responses in WT MEFs revealed that the relative efficacies did not differ substantially between the dependent measures of IP accumulation and  $\text{Ca}^{2+}$  release, in agreement with previous studies (Berg et al., 1998a) (Table 4). By contrast, relative rank orders of efficacy

Agonist potencies ( $EC_{50}$ ) and relative efficacies ( $E_{max}$ ) represent the average of four to five independent experiments.  $pEC_{50}$  values are represented as  $-\log$  of  $EC_{50}$ , given as molar values.

Agonist	Agonist Potency $EC_{50}$ (pEC <sub>50</sub> ± S.E.M.)			Relative Agonist Efficacy $E_{max} \pm$ S.E.M.			$E_{max}^{RSK2KO}/E_{max}^{WT}$
	WT MEFs	RSK2KO MEFs	<i>F</i> Test, <i>p</i> Value	WT MEFs	RSK2 KO MEFs	<i>F</i> Test, <i>p</i> Value	
	<i>nM</i>			<i>%</i>			
5-HT	7.79 (8.11 ± 0.07)	10.2 (7.99 ± 0.17)	0.6969	97.0 ± 2.2	202 ± 12.5	<0.0001	1.5
DOI	2.81 (8.55 ± 0.12)	4.68 (8.33 ± 0.11)	0.2309	87.3 ± 2.9	141 ± 4.6	<0.0001	1.6
Quipazine	22.8 (7.64 ± 0.12)	62.3 (7.21 ± 0.09)	0.0114	88.1 ± 3.6	157 ± 5.7	<0.0001	1.8
5-Methoxy-DMT	60.0 (7.22 ± 0.08)	58.2 (7.24 ± 0.14)	0.9509	83.2 ± 2.6	145 ± 7.8	<0.0001	1.7
Lisuride	985 (6.01 ± 0.17)	1023 (5.99 ± 0.12)	0.9405	29.1 ± 2.7	58.7 ± 3.8	<0.0001	2.0
<i>m</i> -CPP	155 (6.81 ± 0.18)	234 (6.63 ± 0.31)	0.6959	60.5 ± 5.0	116 ± 17	0.0039	1.9
SCH-23390	329 (6.48 ± 0.32)	197 (6.71 ± 0.34)	0.6864	25.7 ± 4.0	33.2 ± 5.2	0.2974	1.3
α-Me-5-HT	25.0 (7.60 ± 0.12)	21.9 (7.66 ± 0.41)	0.9401	106 ± 4.5	212 ± 32	0.0046	2.0
MK212	817 (6.09 ± 0.18)	846 (6.07 ± 0.33)	0.9793	72.5 ± 7.8	168 ± 33	0.1035	2.3


Agonist potencies ( $EC_{50}$ ) and relative efficacies ( $E_{max}$ ) represent the average of four to five independent experiments.  $pEC_{50}$  values are represented as  $-\log$  of  $EC_{50}$ , given as molar values.

Agonist	Agonist Potency $EC_{50}$ (pEC <sub>50</sub> ± S.E.M.)			Relative Agonist Efficacy $E_{max}$ ± S.E.M.			$E_{max}^{RSK2KO}/E_{max}^{WT}$
	WT MEFs	RSK2 KO MEFs	<i>F</i> Test <i>p</i> Value	WT MEFs	RSK2 KO MEFs	<i>F</i> Test <i>p</i> Value	
	<i>nM</i>			%			
5-HT	6.51 (8.19 ± 0.08)	3.92 (8.41 ± 0.11)	0.4729	99.1 ± 3.5	325 ± 15	<0.0001	3.3
DOI	0.370 (9.43 ± 0.16)	0.889 (9.05 ± 0.22)	0.4866	99.0 ± 3.9	348 ± 24	<0.0001	3.5
Quipazine	2.42 (8.62 ± 0.17)	4.24 (8.37 ± 0.20)	0.4796	108 ± 7	270 ± 22	<0.0001	2.5
5-Methoxy-DMT	8.23 (8.08 ± 0.19)	7.45 (8.13 ± 0.19)	0.9356	89.8 ± 7.7	343 ± 29	<0.0001	3.8
Lisuride	7.39 (8.13 ± 0.21)	2.27 (8.64 ± 0.32)	0.5414	90.9 ± 8.3	278 ± 32	0.0010	3.1
<i>m</i> -CPP	21.6 (7.67 ± 0.18)	21.6 (7.67 ± 0.19)	0.9976	105 ± 9	245 ± 25	<0.0001	2.3
SCH-23390	21.2 (7.67 ± 0.29)	3.65 (8.44 ± 0.23)	0.3295	51.3 ± 7.4	202 ± 19	0.0100	3.9
α-Me5-HT	3.07 (8.51 ± 0.19)	3.91 (8.41 ± 0.17)	0.8488	83.4 ± 6.3	327 ± 23	<0.0001	3.9
MK212	133 (6.88 ± 0.13)	42.5 (7.37 ± 0.14)	0.2023	71.2 ± 4.6	261 ± 18	0.0005	3.7




differed significantly comparing measures of IP accumulation and ERK1/2 phosphorylation (Fig. 5A, and Table 4). For example, lisuride and *m*-CPP, which were weak to moderate partial agonists for IP accumulation and Ca<sup>2+</sup> release, maximally activated ERK1/2 in WT MEFs. In agreement with several other studies (Berg et al., 1998a; Kurrasch-Orbaugh et al., 2003), lisuride only weakly activated 5-HT<sub>2A</sub>-mediated IP accumulation (relative  $E_{\max}$  = 17.1 ± 2.6%,  $n$  = 4) and Ca<sup>2+</sup> release (relative  $E_{\max}$  = 29.1 ± 2.7%,  $n$  = 4). However, despite its behavior as a weak partial agonist for IP accumu-

lation and Ca<sup>2+</sup> release, lisuride stimulated ERK phosphorylation similarly to the reference full agonist 5-HT (relative  $E_{\max}$  = 90.9 ± 8.3 and 99.1 ± 3.5% for lisuride and 5-HT, respectively;  $p$  > 0.05). Similar observations were made for the partial agonist *m*-CPP, which was a partial agonist for IP accumulation (relative  $E_{\max}$  = 27.8 ± 2.4%,  $n$  = 5) and Ca<sup>2+</sup> release (relative  $E_{\max}$  = 60.5 ± 5.0%). By contrast, *m*-CPP and 5-HT were equal in their abilities to induce ERK phosphorylation (relative  $E_{\max}$  = 105 ± 9.0 and 99.1 ± 3.5% for *m*-CPP and 5-HT, respectively;  $p$  > 0.05).



**Fig. 3.** The relative efficacies of 5-HT<sub>2A</sub> receptor agonists are globally augmented by genetic deletion of RSK2. Agonist potencies (pEC<sub>50</sub>) and relative efficacies ( $E_{\max}$ ) for IP accumulation (A and B), Ca<sup>2+</sup> release (C and D), and ERK phosphorylation (E and F) in WT and RSK2 KO MEFs were plotted as X-Y correlations. Relative to a line of identity (dashed line),  $E_{\max}$  values were consistently higher in RSK2 KO MEFs, whereas pEC<sub>50</sub> values were similar between cell lines.  $E_{\max}$  and pEC<sub>50</sub> values were calculated via nonlinear regression as reported in Tables 1 to 3. Values represent the mean ± S.E.M. of three to six independent experiments performed in duplicate. Agonists tested were 5-HT (■), DOI (□), quipazine (●), 5-methoxy DMT (○), lisuride (▲), *m*-CPP (△), SCH-23390 (▼), α-Me-5-HT (▽), and MK212 (◆).

As reported above, striking variations in  $E_{\max}^{\text{RSK2KO}}/E_{\max}^{\text{WT}}$  values for IP accumulation suggested that the responses to some agonists were differentially sensitive to genetic deletion of RSK2. Furthermore, these discrepancies could not be explained by agonist class, because RSK2 deletion did not similarly potentiate all partial agonists or full agonists. For



Rank Order	IP Accumulation		Ca <sup>2+</sup> Release		ERK1/2 Phosphorylation	
	WT MEFs	RSK2 KO MEFs	WT MEFs	RSK2 KO MEFs	WT MEFs	RSK2 KO MEFs
1	5-HT (a)	5-Methoxy DMT (a)	a-Me5-HT (a)	a-Me5-HT (a)	Quipazine (a)	DOI (a)
2	a-Me5-HT (a,b)	Quipazine (a)	5-HT (a,b)	5-HT (a)	m-CPP (a)	5-Methoxy DMT (a)
3	Quipazine (b,c)	DOI (a,b)	Quipazine (a,b,c)	MK212 (a)	5-HT (a)	a-Me5-HT (a,b)
4	MK212 (c)	5-HT (a)	DOI (a,b,c)	Quipazine (a,b)	DOI (a,b)	5-HT (a)
5	DOI (c,d)	MK212 (b,c)	5-Methoxy DMT (b,c,d)	5-Methoxy DMT (a,b,c)	Lisuride (a,b)	Lisuride (a,b)
6	5-Methoxy DMT (d)	a-Me5-HT (c)	MK212 (c,d)	DOI (a,b,c)	5-Methoxy DMT (a,b)	Quipazine (a,b)
7	m-CPP (e)	m-CPP (c,d)	m-CPP (d)	m-CPP (a,b,c)	a-Me5-HT (a,b,c)	MK212 (a,b)
8	Lisuride (e,f)	Lisuride (d)	Lisuride (e)	Lisuride (b,c)	MK212 (b,c)	m-CPP (a,b)
9	SCH-23390 (f)	SCH-23390 (d)	SCH-23390 (e)	SCH-23390 (c)	SCH-23390 (c)	SCH-23390 (b)



example,  $E_{\max}^{\text{RSK2KO}}/E_{\max}^{\text{WT}}$  values for the partial agonists 5-methoxy-DMT and DOI were highly responsive to RSK2 deletion, as exhibited by 3.4- and 2.9-fold increases in IP accumulation in RSK2 KO MEFs, respectively. In contrast, the full agonist  $\alpha$ -Me-5-HT was the least responsive to RSK2 deletion, resulting in a meager 1.4-fold increase in IP accumulation in RSK2 KO MEFs. As a result, rank position significantly increased for 5-methoxy-DMT and DOI but not  $\alpha$ -Me-5-HT in RSK2 KO MEFs. Taken together, the unique responsiveness of 5-methoxy-DMT and DOI in the absence of RSK2 most likely explains the conditional efficacy observed for IP accumulation in RSK2 KO MEFs.


## Discussion

The major finding of this article is that patterns of 5-HT<sub>2A</sub> agonist functional selectivity are modulated by genetic deletion of a single kinase. Via high-throughput and high-content technologies, we identified global increases in agonist efficacies but not potencies for 5-HT<sub>2A</sub>-mediated IP accumulation, Ca<sup>2+</sup> release, and ERK1/2 phosphorylation in the absence of

RSK2. These findings imply that 5-HT<sub>2A</sub> receptors are more responsive in the absence of RSK2 (i.e., less desensitized) and confirm our previous reports showing that RSK2 attenuates 5-HT<sub>2A</sub> receptor signaling (Sheffler et al., 2006; Strachan et al., 2009). It is noteworthy that this study shows that patterns of functional selectivity vary depending upon the cellular milieu.

In agreement with many studies demonstrating that ligands elicit a spectrum of receptor behaviors (Urban et al., 2007; Mailman, 2007), including studies at 5-HT<sub>2A</sub> receptors (Berg et al., 1998a; Kurrasch-Orbaugh et al., 2003; Moya et al., 2007), we uncovered novel examples of functional selectivity between 5-HT<sub>2A</sub>-mediated IP accumulation and ERK1/2 phosphorylation in WT MEFs, and between WT and RSK2 KO MEFs at 5-HT<sub>2A</sub>-mediated IP accumulation.

First, we documented functional selectivity in WT MEFs. We identified significant reversals in relative agonist efficacies between effector readouts in WT MEFs. These changes in relative efficacy could be explained either by increased system responsiveness (i.e., cell-based functional selectivity)




**Fig. 5.** Evidence of functional selectivity between measures of IP accumulation and ERK1/2 phosphorylation in WT MEFs. A, relative rank orders of efficacy ( $E_{\max}$ ; 5-HT set to 100%) were significantly altered between measures of IP accumulation (■) and ERK1/2 phosphorylation (□) for 5-HT<sub>2A</sub> agonists in WT MEFs. Statistical ranking of relative  $E_{\max}$  values was performed via one-way ANOVA and Tukey-Kramer multiple comparison post-tests in which agonists were assigned to statistically homogeneous groups (designated "a" through "f" in Table 4, labeled bars). Significant differences in rank order were denoted by changes in group membership, and agonists with nonoverlapping group assignments were considered to be significantly different. Values represent the mean of four to five independent experiments performed in duplicate. B, the relative efficacies of MK212 and m-CPP were reversed between measures of IP accumulation (■) and ERK1/2 phosphorylation (□) in WT MEFs (\*, significantly different from MK212,  $p < 0.05$ ). Labeled bars represent statistically homogeneous groups (designated "a" through "f" in Table 4). C, concentration-response curves showing the relative abilities of MK212 (■) and m-CPP (○) to stimulate IP accumulation via 5-HT<sub>2A</sub> receptors in WT MEFs. Relative  $E_{\max}$  values were significantly different ( $p < 0.05$ ). Values represent the mean  $\pm$  S.E.M. of four to five independent experiments performed in duplicate. D, concentration-response curves showing the relative abilities for MK212 (■) and m-CPP (○) to stimulate ERK phosphorylation via 5-HT<sub>2A</sub> receptors in WT MEFs. Relative  $E_{\max}$  values were significantly different ( $p < 0.05$ ). Values represent the mean  $\pm$  S.E.M. of four to five independent experiments performed in duplicate.

or by changes in the agonist-receptor complex (i.e., receptor-based functional selectivity). Kenakin (2007) has proposed that relative measures of efficacy are system-independent and are solely functions of agonist efficacy. It follows, then, that a reversal in the relative efficacies of two agonists, a hallmark of receptor-based functional selectivity, requires a change in the agonist-receptor complex (i.e., multiple receptor active states). Consistent with reports of receptor-based functional selectivity in the literature, we found that the relative efficacies of *m*-CPP and MK212 were significantly reversed between measures of IP accumulation and ERK1/2 phosphorylation.

It is apparent that the functional selectivity observed for *m*-CPP and MK212 in WT MEFs could be explained by a single activated receptor state and pathway-specific differences in stimulus-response coupling (e.g., receptor reserve for ERK1/2 phosphorylation). It follows, then, that if stimulus-response coupling was primarily enhanced for one pathway (e.g., ERK1/2) over another (e.g., IP accumulation), we would expect to observe increased efficacy for all partial agonists at the more efficiently coupled pathway. This assumption is central to the system-independence of the “intrinsic efficacy” concept, because the strength of signal imparted to the re-

ceptor between two agonists is reflected by the effector response. In functional terms, enhanced stimulus-response coupling manifests as increases in the efficacies of all agonists (i.e., until the response system is saturated), wherein the rank order of efficacy is retained, not reversed (Kenakin, 2009). As presented here, the relative efficacy of the partial agonist MK212 remained unchanged between measures of IP accumulation and ERK1/2 phosphorylation, whereas in the same cells, the relative efficacy of the partial agonist *m*-CPP was 4-fold higher for ERK1/2 phosphorylation than for IP accumulation. These data challenge the system-independent notion of intrinsic efficacy. Moreover, these data agree with previous reports of functional selectivity at 5-HT<sub>2A</sub> receptors, in which partial agonist efficacies (e.g., of quipazine and TFMPP) were not uniform comparing different pathways (Berg et al., 1998b; Kurrasch-Orbaugh et al., 2003).

The second and most intriguing example of functional selectivity at 5-HT<sub>2A</sub> receptors resulted from a comparison between effector readouts in WT and RSK2 KO MEFs. Our findings show that genetic deletion of RSK2 elicits a reversal in the relative rank order of efficacy for IP accumulation. We observed that the relative efficacies for IP accumulation were potentiated to different extents in RSK2 KO MEFs, as illus-



**Fig. 6.** Genetic deletion of RSK2 significantly alters the relative rank order efficacy of 5-HT<sub>2A</sub> agonists: evidence for functional selectivity between WT and RSK2 KO MEFs. A, relative rank orders of efficacy ( $E_{max}$ , 5-HT set to 100%) were significantly altered between WT (■) and RSK2 KO MEFs (□) for 5-HT<sub>2A</sub>-mediated IP accumulation. Statistical ranking of relative  $E_{max}$  values was performed via one-way ANOVA and Tukey-Kramer multiple comparison post-tests in which agonists were assigned to statistically homogeneous groups (designated “a” through “f” in Table 4, labeled bars). Significant differences in rank order were denoted by changes in group membership, and agonists with nonoverlapping group assignments were considered to be significantly different. Values represent the mean of four to five independent experiments performed in duplicate. B, the relative efficacies of  $\alpha$ -Me-5-HT, 5-methoxy-DMT, and DOI were reversed between WT (■) and RSK2 KO MEFs (□) for 5-HT<sub>2A</sub>-mediated IP accumulation (\*, statistically different from  $\alpha$ -Me-5-HT,  $p < 0.05$ ). Labeled bars represent statistically homogeneous groups (designated “a” through “f” in Table 4). C, concentration-response curves showing the relative abilities of  $\alpha$ -Me-5-HT (■), 5-methoxy-DMT (○), and DOI (▲) to stimulate IP accumulation via 5-HT<sub>2A</sub> receptors in WT MEFs. Relative  $E_{max}$  values were significantly different between  $\alpha$ -Me-5-HT and both 5-methoxy-DMT and DOI ( $p < 0.05$ ). Values represent the mean  $\pm$  S.E.M. of four to five independent experiments performed in duplicate. D, concentration-response curves showing the relative abilities of  $\alpha$ -Me-5-HT (■), 5-methoxy-DMT (○), and DOI (▲) to stimulate IP accumulation via 5-HT<sub>2A</sub> receptors in RSK2 KO MEFs. Relative  $E_{max}$  values were significantly different between  $\alpha$ -Me-5-HT and both 5-methoxy-DMT and DOI ( $p < 0.05$ ). Values represent the mean  $\pm$  S.E.M. of four to five independent experiments performed in duplicate.

trated by different  $E_{\max}^{\text{RSK2KO}}/E_{\max}^{\text{WT}}$  values. This suggests that agonist responses are differentially regulated by RSK2. Modest differences between WT and RSK2 KO cell lines cannot account for reversals in relative efficacies because  $\alpha$ -Me-5-HT, which is a full agonist in WT MEFs, exhibited weak partial agonist activity in RSK2 KO MEFs.

From a conceptual perspective, differences in  $E_{\max}^{\text{RSK2KO}}/E_{\max}^{\text{WT}}$  values and reversals in agonist relative efficacy between RSK2 KO and WT MEFs are not entirely surprising, because auxiliary GPCR-interacting proteins, of which there are many (Bockaert et al., 2004; Allen et al., 2008), have the potential to alter ligand activity at target receptors (Christopoulos et al., 2003). This new set of pharmacological behaviors is believed to arise from interactions between ligand-enriched GPCR conformations and auxiliary proteins and has been tentatively termed "conditional efficacy." Indeed, we have shown previously that RSK2 interacts with the 5-HT<sub>2A</sub> receptor third intracellular loop and induces receptor phosphorylation, thereby attenuating receptor signaling (Sheffler et al., 2006; Strachan et al., 2009). Thus, it is conceivable that agonists are disproportionately affected by RSK2-mediated receptor phosphorylation. To support this concept, recent studies have shown evidence of 1) agonist-specific GPCR phosphorylation (Zhang et al., 1998; Roush et al., 1999; Li et al., 2003; Trester-Zedlitz et al., 2005), 2) agonist-specific third intracellular loop conformational changes (Swaminath et al., 2004, 2005), 3) phosphorylation-dependent functional responses (Tobin, 2008), and 4) phosphorylation-mediated stabilization of individual receptor conformations (Francesconi and Duvoisin, 2000; Thomas et al., 2000; Palanche et al., 2001). Although plausible, it remains to be determined how receptor phosphorylation differentially affects agonist signaling. Nevertheless, this is an intriguing hypothesis and warrants further study.

Zidar et al. (2009) demonstrated recently that endogenous CCR7 chemokine receptor ligands differentially activate GRK isoforms, thus leading to differences in receptor phosphorylation and functionally distinct pools of  $\beta$ -arrestin. Differential kinase activation is of fundamental interest to the field of functional selectivity and could perhaps explain the disproportionate effects on agonist signaling in RSK2 KO MEFs. However, considerable evidence argues against this mechanism. First, 5-HT<sub>2A</sub> receptors are known to be regulated by a GRK-independent mechanism in some cell types (Gray and Roth, 2001; Gray et al., 2001). Second, despite numerous attempts by our laboratory and others, agonist-mediated phosphorylation of 5-HT<sub>2A</sub> receptors has never been detected (Sheffler et al., 2006; Strachan et al., 2009; B.L. Roth, unpublished observations). Instead, 5-HT<sub>2A</sub> receptors seem to be constitutively phosphorylated (Vouret-Craviari et al., 1995) and desensitized (i.e., the "tonic brake") (Sheffler et al., 2006), presumably through growth factor-mediated activation of RSK2 (Strachan et al., 2009). Therefore, the most likely hypothesis remains that RSK2-mediated receptor phosphorylation differentially affects agonist signaling.

To our knowledge, this is the first study to demonstrate that deletion of a single kinase leads to differential patterns of functional selectivity at a GPCR. Because it is well known that different cell types express distinct sets of GPCR-interacting proteins and kinases, this study exposes the potential for minor changes in the kinome to elicit large alterations in

effector readouts, with obvious implications for drug actions in vitro and in vivo.

## Acknowledgments

We thank Terry P. Kenakin for discussions concerning functional selectivity, Niels H. Jensen for assistance with the CellProfiler image analysis software, and Douglas J. Sheffler and Vincent Setola for help with receptor density measurements.

## References

- Abbas A and Roth BL (2008) Arresting serotonin. *Proc Natl Acad Sci U S A* **105**: 831–832.
- Allen JA, Yadav PN, and Roth BL (2008) Insights into the regulation of 5-HT<sub>2A</sub> serotonin receptors by scaffolding proteins and kinases. *Neuropharmacology* **55**: 961–968.
- Berg KA, Maayani S, Goldfarb J, and Clarke WP (1998a) Pleiotropic behavior of 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptor agonists. *Ann NY Acad Sci* **861**:104–110.
- Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, and Clarke WP (1998b) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. *Mol Pharmacol* **54**:94–104.
- Berger M, Gray JA, and Roth BL (2009) The expanded biology of serotonin. *Annu Rev Med* **60**:355–366.
- Berry SA, Shah MC, Khan N, and Roth BL (1996) Rapid agonist-induced internalization of the 5-hydroxytryptamine<sub>2A</sub> receptor occurs via the endosome pathway in vitro. *Mol Pharmacol* **50**:306–313.
- Bhatnagar A, Willins DL, Gray JA, Woods J, Benovic JL, and Roth BL (2001) The dynamin-dependent, arrestin-independent internalization of 5-hydroxytryptamine 2A (5-HT<sub>2A</sub>) serotonin receptors reveals differential sorting of arrestins and 5-HT<sub>2A</sub> receptors during endocytosis. *J Biol Chem* **276**:8269–8277.
- Bockaert J, Fagni L, Dumuis A, and Marin P (2004) GPCR interacting proteins (GIP). *Pharmacol Ther* **103**:203–221.
- Bourdon DM, Wing MR, Edwards EB, Sondek J, and Harden TK (2006) Quantification of isozyme-specific activation of phospholipase C- $\beta$ 2 by Rac GTPases and phospholipase C- $\epsilon$  by Rho GTPases in an intact cell assay system. *Methods Enzymol* **406**:489–499.
- Christopoulos A, Christopoulos G, Morfis M, Udawela M, Laburthe M, Couvineau A, Kuwasako K, Tilakaratne N, and Sexton PM (2003) Novel receptor partners and function of receptor activity-modifying proteins. *J Biol Chem* **278**:3293–3297.
- De Deurwaerdere P, Navailles S, Berg KA, Clarke WP, and Spampinato U (2004) Constitutive activity of the serotonin<sub>2C</sub> receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. *J Neurosci* **24**:3235–3241.
- Francesconi A and Duvoisin RM (2000) Opposing effects of protein kinase C and protein kinase A on metabotropic glutamate receptor signaling: selective desensitization of the inositol trisphosphate/Ca<sup>2+</sup> pathway by phosphorylation of the receptor-G protein-coupling domain. *Proc Natl Acad Sci U S A* **97**:6185–6190.
- Frödin M and Gammeltoft S (1999) Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. *Mol Cell Endocrinol* **151**:65–77.
- Galandrin S and Bouvier M (2006) Distinct signaling profiles of  $\beta$ 1 and  $\beta$ 2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. *Mol Pharmacol* **70**:1575–1584.
- Ghosh D, Snyder SE, Watts VJ, Mailman RB, and Nichols DE (1996) 9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-d]elisoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore. *J Med Chem* **39**:549–555.
- Gray JA and Roth BL (2001) Paradoxical trafficking and regulation of 5-HT<sub>2A</sub> receptors by agonists and antagonists. *Brain Res Bull* **56**:441–451.
- Gray JA, Sheffler DJ, Bhatnagar A, Woods JA, Hufeisen SJ, Benovic JL, and Roth BL (2001) Cell-type specific effects of endocytosis inhibitors on 5-hydroxytryptamine(2A) receptor desensitization and resensitization reveal an arrestin-, GRK2-, and GRK5-independent mode of regulation in human embryonic kidney 293 cells. *Mol Pharmacol* **60**:1020–1030.
- Kenakin T (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. *Trends Pharmacol Sci* **16**:232–238.
- Kenakin T (2002) Efficacy at G-protein-coupled receptors. *Nat Rev Drug Discov* **1**:103–110.
- Kenakin T (2007) Functional selectivity through protean and biased agonism: who steers the ship? *Mol Pharmacol* **72**:1393–401.
- Kenakin T (2009) *A Pharmacology Primer: Theory, Application, and Methods*. Elsevier, New York.
- Kroeze WK and Roth BL (1998) The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis. *Biol Psychiatry* **44**:1128–1142.
- Kurrasch-Orbaugh DM, Watts VJ, Barker EL, and Nichols DE (2003) Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. *J Pharmacol Exp Ther* **304**: 229–237.
- Leffkowitz RJ and Shenoy SK (2005) Transduction of receptor signals by  $\beta$ -arrestins. *Science* **308**:512–517.
- Li JG, Zhang F, Jin XL, and Liu-Chen LY (2003) Differential regulation of the human kappa opioid receptor by agonists: etorphine and levorphanol reduced dynorphin A- and U50,488H-induced internalization and phosphorylation. *J Pharmacol Exp Ther* **305**:531–540.
- Mailman RB (2007) GPCR functional selectivity has therapeutic impact. *Trends Pharmacol Sci* **28**:390–396.
- Moya PR, Berg KA, Gutiérrez-Hernández MA, Sáez-Briones P, Reyes-Parada M,



- Cassels BK, and Clarke WP (2007) Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)<sub>2A</sub> and 5-HT<sub>2C</sub> receptors. *J Pharmacol Exp Ther* **321**:1054–1061.
- Palanche T, Ilien B, Zoffmann S, Reck MP, Bucher B, Edelstein SJ, and Galzi JL (2001) The neurokinin A receptor activates calcium and cAMP responses through distinct conformational states. *J Biol Chem* **276**:34853–34861.
- Roth BL and Chuang DM (1987) Multiple mechanisms of serotonergic signal transduction. *Life Sci* **41**:1051–1064.
- Roush ED, Warabi K, and Kwatra MM (1999) Characterization of differences between rapid agonist-dependent phosphorylation and phorbol ester-mediated phosphorylation of human substance P receptor in intact cells. *Mol Pharmacol* **55**:855–862.
- Schmid CL, Raehal KM, and Bohn LM (2008) Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. *Proc Natl Acad Sci U S A* **105**:1079–1084.
- Sheffler DJ, Kroeze WK, Garcia BG, Deutch AY, Hufeisen SJ, Leahy P, Brünig JC, and Roth BL (2006) p90 ribosomal S6 kinase 2 exerts a tonic brake on G protein-coupled receptor signaling. *Proc Natl Acad Sci U S A* **103**:4717–4722.
- Stephenson RP (1956) A modification of receptor theory. *Br J Pharmacol Chemother* **11**:379–393.
- Strachan RT, Sheffler DJ, Willard B, Kinter M, Kiselar JG, and Roth BL (2009) Ribosomal S6 kinase 2 directly phosphorylates the 5-hydroxytryptamine 2A (5-HT<sub>2A</sub>) serotonin receptor, thereby modulating 5-HT<sub>2A</sub> signaling. *J Biol Chem* **284**:5557–5573.
- Swaminath G, Deupi X, Lee TW, Zhu W, Thian FS, Kobilka TS, and Kobilka B (2005) Probing the beta<sub>2</sub> adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. *J Biol Chem* **280**:22165–22171.
- Swaminath G, Xiang Y, Lee TW, Steenhuis J, Parnot C, and Kobilka BK (2004) Sequential binding of agonists to the beta<sub>2</sub> adrenoceptor. Kinetic evidence for intermediate conformational states. *J Biol Chem* **279**:686–691.
- Thomas WG, Qian H, Chang CS, and Karnik S (2000) Agonist-induced phosphorylation of the angiotensin II (AT<sub>1A</sub>) receptor requires generation of a conformation that is distinct from the inositol phosphate-signaling state. *J Biol Chem* **275**:2893–900.

- Tobin AB (2008) G-protein-coupled receptor phosphorylation: where, when and by whom. *Br J Pharmacol* **153** (Suppl 1):S167–S176.
- Trester-Zedlitz M, Burlingame A, Kobilka B, and von Zastrow M (2005) Mass spectrometric analysis of agonist effects on posttranslational modifications of the beta-2 adrenoceptor in mammalian cells. *Biochemistry* **44**:6133–6143.
- Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, and Mailman RB (2007) Functional selectivity and classical concepts of quantitative pharmacology. *J Pharmacol Exp Ther* **320**:1–13.
- Vouret-Craviari V, Auberger P, Pouyssegur J, and Van Obberghen-Schilling E (1995) Distinct mechanisms regulate 5-HT<sub>2</sub> and thrombin receptor desensitization. *J Biol Chem* **270**:4813–4821.
- Willins DL, Berry SA, Alsayegh L, Backstrom JR, Sanders-Bush E, Friedman L, and Roth BL (1999) Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo. *Neuroscience* **91**:599–606.
- Wilson KJ, Gilmore JL, Foley J, Lemmon MA, and Riese DJ 2nd (2009) Functional selectivity of EGF family peptide growth factors: implications for cancer. *Pharmacol Ther* **122**:1–8.
- Zhang J, Ferguson SS, Barak LS, Bodduluri SR, Laporte SA, Law PY, and Caron MG (1998) Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness. *Proc Natl Acad Sci U S A* **95**:7157–7162.
- Zhang JH, Chung TD, and Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. *J Biomol Screen* **4**:67–73.
- Zidar DA, Violin JD, Whalen EJ, and Lefkowitz RJ (2009) Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. *Proc Natl Acad Sci U S A* **106**:9649–9654.

**Address correspondence to:** Dr. Bryan L. Roth, Department of Pharmacology, 4072 Genetics Medicine Building, CB #7365, Chapel Hill, NC 27599-7365. E-mail: bryan\_roth@med.unc.edu